Abstract
New lipid and lipoprotein targets for the treatment of cardiometabolic diseases.
Highlights
Lifestyle and dietary efforts have known benefits for the prevention of cardiovascular disease (CVD) [1, 2]
With CVD as the single largest cause of morbidity and mortality in industrial societies and the significant healthcare burden of obesity and diabetes, it is perhaps not too surprising that a multitude of novel therapeutic approaches are under investigation with many already undergoing early clinical trials in humans
Dr Staels and colleagues focus on recent advances in the understanding of bile acid metabolism as well as the role of farnesoid X receptor (FXR) and TGR5 in lipid, glucose, and energy metabolism
Summary
Lifestyle and dietary efforts have known benefits for the prevention of cardiovascular disease (CVD) [1, 2]. With CVD as the single largest cause of morbidity and mortality in industrial societies and the significant healthcare burden of obesity and diabetes, it is perhaps not too surprising that a multitude of novel therapeutic approaches are under investigation with many already undergoing early clinical trials in humans. Bart Staels and colleagues [11] discuss “Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular diseases”.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
